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Introduction
“Choosing the right drug, and the right dose, for the right patients” 
based on patient’s genetic profile has become a key concept for patient 
care. Pharmacogenomics, the study of the effects of genetics on drug 
responses, is taking on a reality role in patient treatment in various part 
of the world. Accurate genetic profiling of patients to guide drug choice 
or drug dosing has benefited a sizeable number of patients in oncology, 
neurology and many other diseases. In the past decade, genetically-
informed drug use has proven to result in significant improvements 
of clinical outcomes, as well as reduction of avoidable Adverse Drug 
Reactions (ADRs).
Pharmacogenomic Drug Labelings for Over 150 Drugs
As of today, the US Food and Drug Administration (FDA) has 
identified more than 150 drugs with pharmacogenomics biomarkers 
for patient’s drug response or safe drug use (http://www.fda.gov/
Drugs/ScienceResearch/ResearchAreas/Pharmacogenetics/
ucm083378.htm).  These  very  informative  pharmacogenomics 
biomarker labelings serve to remind health-care professionals on the 
use of these drugs in relation to particular genetic make-ups of patients. 
The genetic make-up of an individual can affect one’s response to 
drug exposure and metabolism, risk for adverse side-effects, and most 
importantly, clinical responses. Often, these genetic-related outcomes 
are linked to the presence of genetic variants or genetic polymorphisms 
of drug targets, drug metabolizing enzymes, or other response-related 
disposition genes in the patients, thus making them distinct from the 
general population in terms of patient care and drug administration. 
Thus, special medical attentions are needed for these patients. A decade 
ago, due to the limited pharmacogenomics information and the scarcity 
of drugs requiring such a special genetic attention, the clinical use of 
pharmacogenomic tests in the community were also limited. However, 
the rapid expansion of gene-drug knowledge and increase in the number 
of drugs with “individualized” genetic indications have promoted and 
Abstract
Personalized medicine through Pharmacogenomics: choosing the right drug, and the right dose, for the right 
patients based on patient’s genetic makeup-is gradually being realised in Western countries. Yet, the practice of 
pharmacogenomics in Asian countries lags behind that of the West, but the medical needs for pharmacogenomics 
are expected to surge as better patient care is demanded in Asia. As next-generation sequencing technology 
advances quickly, previous technical challenges for performing pharmacogenomic studies or practices in Asia have 
been mostly resolved. What is lacking in Asia is an effective model of community-wide pharmacogenomics. On the 
delivery front, pharmacists, the drug and dosing professionals, can potentially be the main healthcare providers 
for pharmacogenomic services in Asia. The first large “Genomics for Precision Drug Therapy in the Community 
Pharmacy” in Canada, which is close to its completion, has successfully identified community pharmacists as 
key contact professionals for smooth facilitation and implementation of pharmacogenomics for personalized 
medication. It is anticipated that Asian pharmacists, with appropriate training, can have the capacity to provide expert 
pharmacogenomic supports for both physicians and patients in Asia. 
generalized the use of pharmacogenomics in clinical management in 
Western countries. In the US, the FDA drug genetic biomarker drug 
list has detailed the pharmacogenomic-specific indications for various 
drugs used for cancers, diabetes, psychiatric conditions, cardiology, 
infection, etc. Besides, many common drugs for regular medical uses 
are also on the list, such as codeine, warfarin, celecoxib, etc. In fact, 
the Clinical Pharmacogenetics Implementation Consortium (CPIC) 
of the National Institutes of Health’s Pharmacogenomics Research 
Network has developed gene-drug guidelines (www.pharmgkb.org) 
on new developments relevant for clinicians and researchers. Recently, 
the European Medicines Agency (EMA) and Health Canada (Santé 
Canada) (HCSC) have issued similar pharmacogenomic guidelines and 
drug lists. It is important to note that, Japan, the first country in Asia, 
has also made these pharmacogenomics information available via the 
Pharmaceuticals and Medical Devices Agency (PMDA), Japan. 
Ethnic differences in pharmacogenetic variants distinguishes 
Asian populations
Increasing evidences reveal that the prevalence of pharmacogenetics 
variants in different ethnic groups can be significant (Table 1). 
Obviously, these ethnic differences will ultimately affect the practice 
of safe medication and effective drug use among patients of different 
ethnicity for certain drugs. For example, the CYP2D6 gene encodes an 
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enzyme that breaks down many commonly used drugs in our body. 
Some drugs, such as tricyclic antidepressants (e.g. amitriptyline, 
nortriptyline) are metabolized to inactive forms for elimination by 
our body. However, ethnic genetic differences are widely recognized 
for this gene. Individuals harboring defective CYP2D6 gene alleles are 
poor metabolizers of tricyclic antidepressants, and are prone to develop 
concentration-dependent adverse effects or even therapy failure 
[1]. The prevalence of CYP2D6 poor metabolizer genetics is ~6-10% 
among Caucasians, and ~2% among Asians. In fact, CYP2D6 genetic 
testing is considered medically necessary to guide patient treatment 
with amitriptyline, nortriptyline, and tetrabenazine, etc. Similarly, 
pharmacogenomic testing of CYP2C9 and VKORC1 gene alleles are also 
medically needed to predict responsiveness to anticoagulation therapy 
in patients using warfarin according to the US FDA pharmacogenomic 
information. VKORC1 gene encodes the pharmacologic target of 
warfarin, vitamin K epoxide reductase, and its genetic variants can 
contribute to differences in warfarin sensitivity. Single nucleotide 
polymorphisms in the VKORC1 gene (e.g., –1639G>A) are associated 
with variable warfarin dose requirements (e.g. the AA genotype is found 
in warfarin-sensitive patients). The allele frequencies for AA genotype 
(which will require a lower warfarin dose) is 14.2% in Caucasians 
as compared to 82.1% in Chinese [2]. In fact, it is recommended in 
the FDA approved drug label that VKORC1 and CYP2C9 genotype 
information, when available, shall be used in selection of both the initial 
and maintenance dose of warfarin. Similarly, genetic testing for the 
CYP2C19 for poor or intermediate metabolizer genetics is considered 
medically necessary for patients with acute coronary syndrome (ACS) 
and those undergoing percutaneous coronary intervention with 
clopidogrel (an antiplatelet drug to inhibit blood clots). As high as 
15-20% Asians are known to be poor metabolizers with no functional 
CYP2C19 versus only 3-5% in Caucasians. It is recognized that Asian 
population requires special attention when clopidogrel is prescribed [3]. 
Another example is carbamazepine, an anticonvulsant and specific 
analgesic for trigeminal neuralgia. Carbamazepine has been found to 
be associated with serious and sometimes fatal dermatologic reactions, 
including Toxic Epidermal Necrolysis (TEN) and Stevens-Johnson 
syndrome (SJS). Retrospective case-control studies have found that an 
inherited variant of the HLA-B gene, HLA-B*1502, which is common 
in Chinese, is a marker for carbamazepine-induced SJS and TEN in 
Han Chinese. The prevalence of HLA-B*1502 is >15% in Hong Kong, 
~10% in Taiwan, but largely absent (0-1%) in Caucasians (FDA NDA 
016608, from www.accessdata.fda.gov/scripts/cder/daf/index.cfm). 
Other examples include the use of codeine, an analgesic and cough 
suppressant, individuals with the ultra-rapid metabolizer genetics 
(e.g. CYP2D6 gene duplications (*1/*1 × N or *1/*2 × N)) can cause 
life-threatening conditions or even deaths as they metabolize codeine 
rapidly into morphine. Such fast-metabolizer genetics of codeine occurs 
in 1-10% of Caucasians versus 0.5-1% in Chinese and Japanese (FDA 
NDA 206323). These are just a handful of examples of some drugs to be 
used with special attention based on ethnic differences. With more new 
drugs and more pharmacogenomic research on Asian populations, 
more and more clinically relevant gene-drug information will emerge.
As for oncology treatment, there are specific pharmacogenomic 
markers to be highlighted for Asians. According to the latest cancer 
statistics in China, lung cancer is the most common cancer, followed 
by cancers of the stomach, esophagus, liver, and colorectal [4]. For 
lung cancers, activating mutation of the epidermal growth factor 
receptor (EGFR) gene is a responder genotype for EGFR tyrosine kinase 
inhibitors (TKIs) which is enriched in Asian non-small cell lung cancer 
(NSCLC). NSCLC patients with EGFR activating mutations are highly 
responsive to EGFR TKIs (Table 1). As EGFR activating mutations can 
be as common as 50-60% of lung adenocarcinoma patients in Asia-
Pacific versus only 12-13% in UK and the US [5,6], genetic testing for 
EGFR mutation in Asian lung cancer patients is almost essential prior to 
treatment selection. Such a current clinical practice in Asia was initiated 
by a Pan-Asia study showing marked improvements in progression-
free survival (PFS) in advanced NSCLC patients with EGFR activating 
mutations [7]. Interestingly, for colon cancer, BRAF(V600E) activating 
mutation is a biomarker for poor prognosis, and the presence of KRAS 
mutations predict resistance to EGFR TKI in advanced cases. A recent 
study showed that Asian colorectal cancers are more likely to be BRAF 
wildtype and without KRAS mutations, implicating a significantly lower 
frequency of occurrence of a resistance genotype to EGFR TKI in Asian 
colorectal cancer patients [8]. As for other Asian-prevalent cancers, 
such as liver cancer [9], esophageal cancer [10], and nasopharyngeal 
cancer [11], the genomic findings have recently been revealed and it is 
anticipated that more pharmacogenomic biomarkers will be developed 
in the near future. 





more common in Caucasians (1-10%) and less in Chinese and 
Japanese (0.5-1%)B.
Warfarin Cardiology or Hematology VKORC1 A allele carriers (e.g.,  –1639G>A)
Allele frequencies for AA genotype (lower warfarin dose 
requirement): 14.2% in Caucasians versus 82.1% in Chinese 
[2].
Amitriptyline Psychiatry CYP2D6 poor metabolizers ~6-10% in Caucasians vs ~2% in Asians[1]
Clopidogrel Cardiology CYP2C19 poor metabolizers poor metabolizers: 3-5% in Caucasian vs 15-20% in Asians[3]
Carbamazepine Neurology HLA-B*1502  allele carriers
>15% in Hong Kong, about 10% in Taiwan, but largely absent 
(0-1%) in CaucasiansC.
Erlotinib Oncology
EGFR exon 19 
deletion or  
exon 21 substitution 
(L858R) positive
EGFR activating mutation frequencies: ~ 50-60% of NSCLC in 
Asia-Pacific versus only 12-13% in UK [5].
Irinotecan Oncology UGT1A1*28  allele carriers
Allele frequencies for UGT1A1 7/7 genotype (high incidence of 
neutropenia) is 12-13% in Caucasians, 23% in Blacks and lower 
(2-8%) in Asians [2,12].       
AAS in FDA; Table of pharmacogenomic biomarkers in drug labeling (http://www.fda.gov/Drugs/ScienceResearch/ResearchAreas/Pharmacogenetics/ucm083378.htm);
 BFDA NDA 206323 from www.accessdata.fda.gov/scripts/cder/daf/index.cfm; 
CFDA NDA 016608 from www.accessdata.fda.gov/scripts/cder/daf/index.cfm.
Table 1: Examples of drugs exhibiting ethnic differences in pharmacogenomic variants.
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Immunotherapy is a very promising effective anticancer therapy, 
which sought to awaken the host’s immune response to elicit specific 
anti-tumor activity against one’s tumor. Many new humanized 
monoclonal antibodies or inhibitors against the Programmed cell 
death protein 1 (PD-1) or its ligand (PD-L1) have been developed 
recently. As far as pharmacogenomics is concerned, the use of the FDA 
approved anti-PD-1 antibody pembrolizumab for NSCLC, (as well as 
for head and neck cancer, and melanoma) is recommended as a first-
line therapy for NSCLC tumors with wildtype EGFR or ALK genes. 
It should be noted that since EGFR mutations are more common in 
Asian NSCLC, the mutational status of EGFR (as well as ALK) should 
be determined before the use of pembrolizumab. Note that many 
additional inhibitors against other immune checkpoints or immune 
escape mechanisms are currently under development, and whether 
there are genetic components associated with responses or resistance 
to these new therapies remain to be determined.
Besides drug efficacy, some chemotherapy, such as Irinotecan, 
are also known to display a pharmacogenomic difference for its 
associated adverse drug reaction. For instance, the incidence of grade 4 
neutropenia in patients who are homozygous for the UGT1A1*28 allele 
(UGT1A1 7/7 genotype) has a 50% incidence of grade 4 neutropenia, 
versus 12.5% and 0% incidences in patients with heterozygous UGT1A1 
6/7 genotype and homozygous wild-type allele (UGT1A1 6/6), 
respectively. This Irinotecan risk homozygous genotype (UGT1A1 7/7) 
varies among different ethnic groups. It occurs in 12-13% Caucasians, 
higher (23%) in Blacks and lower (2-8%) in Asians [2,12]. Thus, the 
preferred use or cautious use of cancer therapies can be guided by the 
pharmacogenomic profiles of patients.
Current Status of Pharmacogenomic Practices in Asia
For over a decade, the distinct higher prevalence of EGFR-
activating mutations in Asian NSCLC patients has unexpectedly 
catalysed the initial use of genetics to guide effective drug treatment 
of NSCLC in Asia. Now, EGFR genetic test has become a standard test 
upon the diagnosis of lung adenocarcinoma to guide drug choice in 
many parts in Asia. Some of these tests are funded by public hospitals 
in Asia. However, a decade has passed and challenges are emerging 
when pharmacogenomics demands on multiple diseases are rising in 
Asia. The current status in more medically advanced regions in Asia is 
that molecular tests which are critical for guiding treatments with well-
proven clinical benefits are usually adopted (either in public or private 
settings). However, pharmacogenomic tests that will not directly guide 
treatments are less commonly used. For instance, pharmacogenomic 
tests, like UGT1A1 test that are used for assessing the risk of drug 
toxicity are seldom used in Asia as it is generally accepted by clinicians 
that these tests can be easily replaced by intensive monitoring of 
side effects. The successful implementation of pharmacogenomic 
testing will require the availability and affordability of technologies 
for rapid and reliable genetic analysis, the availability of solid Gene-
Drug knowledge, and most importantly, an effective model on how 
to run and implement pharmacogenomics in clinical and community 
settings. Recent advances in Western countries have resolved 
some of these technological challenges so that rapid and reliable 
pharmacogenomics testing, including the use of Next-Generation 
Sequencing (NGS) can be achieved in a relatively robust manner, even 
in Asia. Pharmacogenomic tests are becoming more affordable than 
ever as the actual cost of sequencing has dropped exponentially in the 
last 15 years from about 8000 US dollars per raw megabase of DNA 
sequence to about 0.01 US dollar in 2015. On the knowledge front, 
the world’s Gene-Drug knowledge are growing exponentially as basic 
and translational pharmacogenomic research data are accumulating. 
As mentioned above, over 150-200 drugs are already available with 
pharmacogenetic information for drug use as approved by main 
regulatory bodies in various parts of the world. Today, most of these 
technical challenges are being resolved in Western countries. Yet in 
Asia, it is clear that a large number of well-trained experts in NGS, 
and gene-drug knowledge, especially on those genetic information 
that are particularly relevant for Asian populations, are much needed 
in order to support a large population of Asian patients demanding 
pharmacogenomic care. 
Pharmacists in Pharmacogenomics
Both the Western world and Asia are facing the same challenge of 
“how to run pharmacogenomics with high practicality in the hospital 
or community settings?” Several survey studies were carried out in 
Western countries to investigate what models were the best for the 
implementation of pharmacogenomics for the community, and different 
models have been proposed [13,14]. In some of these early models, 
pharmacists, the recognized pharmacotherapy professional, have been 
proposed to provide and support the pharmacogenetics care with 
physicians. It is obvious that with the growing pharmacogenomic details 
on drug use and the growing number of drugs with pharmacogenomic 
and dosing indications, physicians alone cannot effectively bear the 
load for the community. On the other hand, pharmacists are well-
trained drug experts and medical professionals who have long been 
involved in identifying potential adverse reactions, drug interactions 
and conduct direct patient counselling on drug use. In both the US and 
the UK, evolutions of healthcare and pharmacy practice have created 
opportunities for pharmacists to take on new roles and expand their 
services [15]. Contemporary pharmacy practice has evolved from one 
where the pharmacist primarily supervises medication distribution and 
counsels patients, to a more expanded clinical role in providing patient-
centred medication therapy management, health improvement, and 
disease prevention services in a team-care setting [15-17]. It would only 
seem natural that pharmacy practice be further expanded to include 
pharmacogenomics service to meet the increasing patient demands 
on a more thorough understanding of gene-drug or dosing details. In 
fact, the National Genetics Education and Development Centre in the 
UK had held a meeting in collaboration with Royal Pharmaceutical 
Society to identify the role played by pharmacists as the provider of 
the pharmacogenetics service [18]. They have recognised the role of 
pharmacists in providing the pharmacogenetics care to the public. 
In addition, they also identified some additional educational needs 
in genetics/pharmacogenetics to allow pharmacists to fulfil this 
expert role adequately in the coming future. This can potentially be 
achieved through a pharmacogenetics inclusive curriculum during 
their professional training and continuing education of practising 
pharmacists. 
In fact, in Canada (British Columbia), the first large “Genomics for 
Precision Drug Therapy in the Community Pharmacy” study, which 
primarily involves the community pharmacists as the patient-contact 
professionals to conduct pharmacogenomic tests in the community, 
is close to its completion soon. This large study involves thirty-
three community pharmacies with practising pharmacists who are 
pharmacogenomically trained to educate, counsel and collect samples 
from community volunteered patients for direct pharmacogenomics 
testings. Post-sample collection, pharmacogenomic testing of 158 gene 
positions is performed at the University of British Columbia. This is the 
first, and the largest community pharmacogenomic implementation 
and feasibility study, which is focused on investigating the model 
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of provision of pharmacogenomics service through community 
pharmacies, where pharmacists are the main healthcare providers 
for this service. Upon determination of the genetic information 
of the patients, those patients with “flagged” genetic variants are 
recommended for therapy suggestions or modifications by the trained 
pharmacists. In the preliminary results, pharmacists indicated that 
patients were doing this pharmacogenomic testing mainly because 
of three reasons: ineffective current drug therapy, wanting to address 
an adverse drug reaction, and to guide the initiation of a therapy. 
Upon the pharmacogenomic testings, pharmacists had recommended 
change in drug therapy, modification of drug dosing, discontinuation 
of the current drug, as well as increased levels of monitoring of 
patients. Importantly, physicians showed positive feedbacks though 
detailed findings are anticipated to be reported likely this year (www.
bcpharmacy.ca/genome). 
In Asia, the Asian physician-based care model makes it a 
real challenge for efficient implementation of a wide range of 
pharmacogenomic services as compared to the Western team-
care model for patient care. In order to run pharmacogenomics 
effectively in Asia under the physician-based care model, physicians 
will need to be trained extensively to make them familiarized with 
every pharmacogenomic detail of all old and new drugs. In theory, 
physicians alone may potentially fulfil this role. However, in Asia, 
with the large patient population and the extreme low physician to 
patient ratio (~only 1-1.9 physicians per thousand population vs. 3.3-
3.7 physicians per thousand population in the US and the UK), the 
relatively short time of consultation in public hospital settings, and 
the often unilateral physician-patient communication among Asian 
physicians [19], detailed pharmacogenomics counselling delivered 
by physicians to patients is not ideal. This is further complicated 
by the ever-increasing number of drugs with pharmacogenomics 
guidelines, indications and ethnic-specific details. Although genetic 
counsellors have been proposed in a study to be co-provider of this 
pharmacogenomic service alongside pharmacists in the US [13], the 
very low number of genetic counsellors in Asia makes this an unlikely 
option. As suggested by the emerging models in Canada and the UK, 
pharmacists, with some pharmacogenomic training, can effectively 
take up a healthcare professional role and provide a large workforce 
to provide pharmacogenetics care with professional counselling to the 
patients and public in Asia. 
Conclusion
Currently, pharmacists’ role in Asia is mainly drug distribution, 
and clinical pharmacy is in its early stage of development, particularly 
in the community setting. Asian pharmacists, with appropriate 
pharmacogenomic training, can have the capacity to provide 
pharmacogenomic supports to physicians and patients provide 
counselling, as well as professional drug use or dosing advices. 
Therefore, it is strategically important to expand pharmacy education 
to ensure appropriate undergraduate and post-graduate training 
in pharmacogenomics in Asian countries to meet the upcoming 
pharmacogenomic demands in Asia. Furthermore, with the currently 
noted ethnic differences in many pharmacogenetic variants for various 
medications, Asian pharmacists and pharmacy researchers are uniquely 
posed to lead or be involved in Asian population-based pharmacogenomic 
studies to discover new Asian-prevalent pharmacogenetics variants to 
improve patient care in this part of the world. Lastly, an Asian network, 
similar to that of the Canadian Pharmacogenomics Network for Drug 
Safety (CPNDS) efforts may identify new predictive genomic biomarkers 
for severe ADRs among Asians [20]. 
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